Deciphering immune landscapes: an ICD-lncRNA-derived prognostic signature for pancreatic adenocarcinoma

We developed and validated a prognostic signature based on six ICD-associated lncRNAs, demonstrating its significant accuracy in predicting outcomes for PAAD patients. This signature holds potential for providing more precise clinical guidance. Furthermore, our preliminary bioinformatic analyses suggest associations between the signature and immune processes, warranting future mechanistic investigation. Additionally, modulating LINC00705 expression may offer a promising strategy to inhibit cancer cell growth and metastasis.